Biogen, the pharmaceutical firm behind the development of an Alzheimer's treatment drug, has issued an announcement about its findings from a clinical trial for lecanemab. Biogen expects the FDA to approve the drugs use shortly. Whether lecanemab is the 'breakthrough' drug for the mitigation of amyloid is being debated, as the results of the clinical trials show positive clinical outcome, but had a limited effect on mitigating cognitive decline. A useful commentary on this drug appears in the 3 December 2022 issue of The Lancet - Lecanemab for Alzheimer’s disease: tempering hype and hope. Interestingly, while the clinical trials included Spanish-language and African American participants, no persons with neurodiverse or neuroatypical conditions were included